STOCKHOLM, Dec. 14, 2023 /PRNewswire/ -- The Consumer
Tissue Private Label Europe business remains a part of
the Essity Group and thereby the strategic review of the
division, which began on April 26 of
this year, is concluded.
Essity continuously evaluates its various businesses to increase
long-term value creation. In the strategic review of Consumer
Tissue Private Label Europe it was concluded that the business as a
result of the implemented divisionalization, is a competitive and
value-creating part of Essity.
Net sales for the Consumer Tissue Private Label Europe business
amounted to approximately SEK 9.8bn
in 2022. The business encompasses seven production facilities in
Belgium, France, Germany and Italy with approximately 1,900
employees.
NB: This is information that Essity Aktiebolag (publ) is
obliged to make public pursuant to the EU Market Abuse Regulation.
The information was submitted for publication, through the agency
of the contact person set out below, at 17:30 CET on December
14, 2023.
Karl Stoltz, Media Relations
Director, +46 709 42 63 38
CONTACT:
For further information, please contact:
Per Lorentz, Vice President
Corporate Communications, +46 73 313 30 55,
per.lorentz@essity.com
Sandra Åberg, Vice President Investor Relations, +46 70 564 96 89,
sandra.aberg@essity.com
The following files are available for download:
|
https://mb.cision.com/Main/15798/3891772/2494179.pdf
|
Strategic review of the
Consumer Tissue Private Label Europe business concluded
|
View original
content:https://www.prnewswire.co.uk/news-releases/strategic-review-of-the-consumer-tissue-private-label-europe-business-concluded-302015873.html